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Background: The bipolar spectrum disorders are considered an important and frequent 
  psychiatric problem. The clinical complexity of these illnesses due to the coexistence of   depressive 
and excitative phases is correlated with the global difficulty of adequate treatment; consequently, 
the prognosis is not optimal. For this reason, in recent years, novel nonpharmacologic physical 
approaches have been tested for bipolar disorders, with encouraging results. The aim of this 
study was to evaluate the long-term effectiveness of a radioelectric asymmetric brain stimulation 
device associated with lithium (REAC-lithium) versus previous treatments in subjects with 
bipolar disorder I or II, evaluated as the number of recurrences compared with the period of 
illness preceding treatment with REAC-lithium.
Methods: The charts of 56 bipolar patients attending our institute were retrospectively evaluated. 
Treatment with REAC-lithium was administered following the standard Rinaldi-Fontani Institute 
protocol. Add-on treatments were allowed in the event of manic or depressive recurrence. Eight 
patients (Group 1) were followed for 30.2 ± 3.0 months, 14 patients (Group 2) were  followed 
for 25.3 ± 3.3 months, 25 patients (Group 3) were followed for 20.3 ± 1.6 months, and nine 
patients (Group 4) were followed for 16.2 ± 0.5 months.
Results: After REAC-lithium treatment, the number of manic and depressive episodes in Group 1 
decreased from 2.1 ± 0.6 and 3.0 ± 0.7 to 0.12 ± 0.0 and 0.8 ± 0.4, respectively. In Group 2, the 
number of manic and depressive episodes decreased from 2.4 ± 0.6 and 3.9 ± 0.7 to 0.14 ± 0.2 
and 0.0 ± 0.0, respectively. In Group 3, the number of manic and depressive episodes decreased 
from 2.6 ± 0.8 and 3.6 ± 0.9 to 0.04 ± 0.0 and 0.0 ± 0.0, respectively. In Group 4, the number of 
manic and depressive episodes decreased from 2.6 ± 1.1 and 3.7 ± 1.0 to 0.1 ± 0.0 and 0.0 ± 0.0, 
respectively. All results were statistically significant.
Conclusion: REAC showed good efficacy in treating both the manic and depressive phases 
of bipolar disorder, and in the prevention of recurrences/relapses.
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Introduction
The concept of the “bipolar spectrum” as a consequence of more accurate diagnos-
tic assessment has progressively increased the classic epidemiologic boundary of 
bipolar disorder,1 historically affecting 0.8%–1.5%2 to 15%3 of the general population. 
In the same way, the complexity of the illness has posed the need for dimensional 
(cross-sectional and longitudinal) monitoring of the patient, in order to design more 
personalized and phase-specific therapeutic strategies. Thus, from a therapeutic point 
of view, the classic drugs for bipolar disorder (lithium, carbamazepine, valproic acid, 
antidepressants, and neuroleptics)4 have been progressively supported with the new Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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generation of anticonvulsants (topiramate, gabapentin, 
pregabalin, lamotrigine, and levetiracetam),5,6 and the atypical 
antipsychotics.7,8 Although the excitative phases (manic and 
hypomanic) are usually considered as the organizing   principle 
of bipolar disorder,4 pooled data for the disease course show 
that, with exclusion of free intervals, nearly 70% of the 
  “bipolar life” consists of depressive episodes and the remain-
ing 30% consists of excitative phenomena.9,10 The main result 
of this hierarchical approach, based on the course of bipolar 
disorder, is a different pharmacologic treatment strategy for 
the manic phenomena and for bipolar depression.11,12 Despite 
recent efforts,13 the results of treatment of bipolar depression 
are not encouraging.14 The use of lamotrigine, after an initial 
enthusiastic introduction, has gradually reduced as an acute 
antidepressant in patients with bipolar disorder, and is cur-
rently used for the prevention of depressive recurrences.15–17 
New pharmacologic data for atypical antipsychotics could be 
considered promising. These drugs seem to be useful in the 
depressive phase (without a manic switch) and in the manic 
phase, avoiding the depressive and apathetic motivational risk 
associated with the administration of typical antipsychotics. 
Unfortunately, the data available regarding the role of these 
drugs in the maintenance of bipolar disorder are fewer than 
expected.8 Moreover, it is important to emphasize that lithium 
remains the first-choice drug for bipolar disorder. However, 
because of the demonstrated and specific antimanic effect, the 
attempt to avoid the excited phases of bipolar disorder often 
produces a stabilization of patient mood, with a progressive 
deterioration of quality of life and reduced energy levels and 
motivation.18,19 Beyond psychopharmacologic treatment, other 
therapeutic strategies for bipolar disorder are available. The 
most studied of these is electroconvulsant therapy, probably the 
most effective treatment in the overall management of bipolar 
disorder, and in recent years, growing data favor transcranic 
magnetic stimulation. The radioelectric asymmetric conveyor 
(REAC) is a radiofrequency medical device based on an inno-
vative technology for brain stimulation. REAC treatment is a 
novel approach for treatment of several mental disorders, and 
the results over time are very encouraging.20–25 The aim of this 
study was to evaluate the long-term effectiveness of REAC 
treatment associated with lithium (REAC-lithium) versus 
previous treatments in subjects with bipolar disorder I and II, 
evaluated as the number of recurrences compared with the 
period of illness preceding REAC-lithium treatment.
Methods and materials
The charts of 56 patients attending the Rinaldi-Fontani 
  Institute in Florence and the Centro di Studi Psichici in 
Cagliari were retrospectively evaluated. Patients diagnosed 
with bipolar disorder I or II according to the revised fourth 
edition of the Diagnostic Statistical Manual for Mental 
  Disorders (DSM-IVTR) criteria were included. Inclusion 
criteria were as follows: both genders; age 18–65 years;   written 
informed consent obtained; history of at least 12 months of 
psychopharmacologically treated bipolar disorder I/II; and 
at least four cycles of REAC treatment. Exclusion criteria 
included a history of seizures, head trauma, or brain disease, 
and evidence of chronic or severe disease (renal or hepatic 
impairment, or cancer). REAC treatment was administered fol-
lowing the standard Rinaldi-Fontani Institute schedule of one 
session of neuropostural optimization followed by 18 sessions 
of neuropsychophysical optimization. Add-on treatments 
were allowed in the event of manic or depressive recurrence. 
Patients were divided into four follow-up groups before and 
after REAC-lithium treatment, as follows: at least 72 months 
(Group 1); at least 48 months (Group 2); at least 36 months 
(Group 3); and at least 18 months (Group 4). Information 
on demographic variables, psychiatric history, concomitant 
treatments, and comorbid disorders were collected for each 
patient. The evaluation of REAC-lithium effectiveness was 
made by collecting the recurrence of mood episodes (manic or 
depressive according to DSM IV-TR). The Structured Clinical 
Interview for Diagnosis, the 21-item Hamilton Depression 
Rating Scale, and the Young Mania Rating Scale (YMRS) 
were been used. Statistical analysis was performed using a 
t-test for comparative groups, and all results with a P , 0.05 
were considered significant. Tolerability and safety were eval-
uated by collecting the reports of adverse events. Demographic 
variables and the psychiatric-psychopharmacologic history of 
the patients are reported in Table 1. Eight patients (Group 1) 
were followed for 30.2 ± 3.0 months, 14 patients (Group 2) for 
25.3 ± 3.3 months, 25 patients (Group 3) for 20.3 ± 1.6 months, 
and nine patients (Group 4) for 16.2 ± 0.5 months. Lithium 
was dosed at 980.0 ± 135.6 mg/day, 825.0 ± 50.0 mg/day, 
850.5 ± 100.0 mg/day, and 950.5 ± 75.5 mg/day in the four 
groups of patients, respectively. The demographic vari-
ables and psychiatric history of the patients are reported 
in Table 1.
REAC26,27 is a medical device based on innovative tech-
nology for biostimulation . REAC works with a typical range 
frequency of 2.4, 5.8, or 10.5 gHz, as selected by the operator 
for each specific protocol used. A frequency of 10.5 gHz was 
used in the brain stimulation protocols used in this study, with 
a specific absorption rate28–30 of 7 µW/kg. REAC treatments 
have proven efficacy in ameliorating stress-related disorders, 
depression, and anxiety.20–25 The REAC pulse used in this Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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study was a 7 radiofrequency burst of 500 msec, applied 
by touching the metallic tip of the REAC probe to the ear 
  pavilion using neuropostural optimization and neuropsy-
chophysical optimization protocols. The treatments are pain-
less, noninvasive, and without negative adverse effects.
Results
Before reAc-lithium therapy
Mean baseline and onset ages for Group 1 (seven males and 
one female; all bipolar disorder I) were 31.4 ± 2.9 years 
and 23.9 ± 2.7 years, respectively. The mean numbers of 
previous manic and depressive episodes per patient were 
2.1 ± 0.6 and 3.0 ± 0.7, respectively, and the overall   number 
of hospitalizations was seven (five due to depressive episodes 
and two due to a manic mood state). Bipolar disorder onset 
was depressive in three patients and manic in five patients. 
All patients in Group 1 had comorbid pathologic gambling. 
Lithium was satisfactory for mood disorder, but ineffective 
for pathologic gambling. The switch to REAC-lithium treat-
ment occurred during a depressive phase in three subjects 
and during the depression-free period in the remaining 
four patients. Mean baseline and onset ages for Group 2 
(seven males [four bipolar disorder I and three bipolar 
disorder II], and seven females [all bipolar disorder II]) 
were 29.9 ± 5.0 years and 21.2 ± 4.2 years, respectively. 
Mean numbers of previous manic and depressive episodes 
per patient were 2.4 ± 0.6 and 3.9 ± 0.7, respectively, with 
an overall number of nine hospitalizations for depressive 
episodes. The onset of bipolar disorder was depressive in 
nine patients and manic in five patients. Patients in Group 2 
were treated with lithium alone (n = 6), lithium added on to 
valproate (n = 3), lithium added on to olanzapine (n = 2), 
lithium added on to fluoxetine (n = 1), and carbamazepine 
(n = 2). The switch to REAC-lithium treatment occurred 
during a depressive phase in nine subjects and during the 
free period in the remaining five patients.
Mean baseline and onset ages for Group 3 (11 males 
[four bipolar disorder I and seven bipolar disorder II], 
and 14 females [three bipolar disorder I and 11 bipolar 
disorder II]) were 28.3 ± 3.7 years and 21.0 ± 3.5 years, 
  respectively. The mean numbers of previous manic 
and depressive episodes per patient were 2.6 ± 0.8 and 
3.6 ± 0.9, respectively, with an overall number of seven 
hospitalizations (four for depressive episodes and three 
for manic episodes). The onset of bipolar disorder was 
depressive in 17 patients and manic in eight patients. 
Ten patients were treated with lithium alone, six with 
lithium added on to valproate, three with lithium added 
on to olanzapine, one with lithium added on to sertraline, 
two with lithium added on to imipramine, and three with 
carbamazepine. The switch to REAC-lithium treatment 
occurred during a depressive phase in 15 subjects and dur-
ing the free period in the remaining 10 patients.
Mean baseline and onset ages for Group 4 (three males 
[one bipolar disorder I and two bipolar disorder II], and six 
females [two bipolar disorder I and four bipolar disorder II]) 
were 30.0 ± 3.9 years and 23.1 ± 4.0 years, respectively. The 
mean number of previous manic and depressive episodes were 
2.6 ± 1.1 and 3.7 ± 1.0, respectively, with an overall number 
of two hospitalizations (one due to a depressive   episode and 
one due to a manic episode). The onset of bipolar disorder 
was depressive in seven patients and manic in two patients. 
Previous treatments were as follows: lithium alone (n = 2); 
lithium added on to valproate (n = 3);   olanzapine (n = 1); 
and lithium added on to citalopram (n = 3). The switch to 
REAC-lithium treatment occurred during a depressive phase 
in five subjects and during the free period in the remaining 
four patients.
Table 1 Overall demographic variables and psychiatric history 
before reAc-lithium treatment
gender, n (%)
  Male 28 (50.0)
  Female 28 (50.0)
Age, years
  Mean (sD) 29.5 (3.9)
  range 25–32
Onset age, years
  Mean (sD) 22.3 (3.6)
  range 19–26
Diagnosis, n (%)
  BD i 22 (39.3)
  BD ii 34 (60.7)
Type of onset, n (%)
  Manic 20 (35.7)
  Depressive 36 (64.3)
episodes/patient mean (sD)
  Manic 2.4 (0.8)
  Depressive 3.6 (0.8)
hospitalization, n
  reason: excitative episode 6
          Depressive episode 19
Previous treatments, n
  Lithium alone 26
  carbamazepine 5
  Olanzapine 1
  Lithium + valproate 12
  Lithium + olanzapine 5
  Lithium + ssri 5
  Lithium + imipramine 2
Abbreviations: BD, bipolar disorder; sD, standard deviation; ssri, selective serotonin 
reuptake inhibitor.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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After reAc-lithium therapy
Tables 2–5 and Figures 1–4 compare the overall mood epi-
sodes (manic and depressive) per Group before and after 
REAC-lithium treatment. In Group 1, three manic and one 
depressive episode occurred. In terms of percentages, there 
were 0.1 depressive episodes per patient and 0.8 ± 0.4 excita-
tive episodes per patient, which was statistically significant 
in comparison with previous treatments (P , 0.001 [t-test]). 
Manic episodes occurred during months 19, 22, and 23 of 
REAC-lithium treatment. All manic episodes were mild 
(YMRS scores of 24, 23, and 23, respectively), and their mean 
duration was 8.0 ± 0.9 weeks. The lithium dose was increased 
by approximately 20%, and valproic acid 1000 mg/day and 
zuclopenthixol 100 mg/day in one case and zuclopenthixol 
125 mg/day and clonazepam 6 mg/day in the remaining two 
patients. The depressive episode, classified mild (Hamilton 
Depression Rating Scale = 21) occurred during month 23 of 
treatment with REAC-lithium treatment and was resolved by 
means of augmentation with bupropion 300 mg/day over a six-
week period. In Group 2, only two manic episodes occurred 
during months 16 and 19 of REAC-lithium treatment. In terms 
of percentages, there were 0.11 ± 0.2 excitative episodes per 
patient, which was statistically significant in comparison 
with previous treatments (P , 0.001 [t-test]). Both were mild 
(YMRS = 22) with a mean length of 7.2 ± 0.3 weeks and were 
treated with valproate 1000 mg/day and zuclopenthixol (mean 
dose 87.5 ± 17.7 mg/day). In Group 3, the one manic episode 
which occurred during month 17 of REAC-lithium treatment 
was mild (YMRS = 25), with a length of 8.0 weeks and treat-
ment with zuclopenthixol 75 mg/day and clonazepam 6 mg/
day. In terms of percentages, there were 0.4 excitative episodes 
per patient, which was statistically significant in comparison 
with previous treatments (P = 0.000 [t-test]). In Group 4, 
one manic episode occurred during month 13 of REAC-
lithium treatment and was mild (YMRS = 24) with a length 
of 10.0 weeks and treatment with zuclopenthixol 75 mg/day 
and valproate 1000 mg/day. In terms of percentages, there 
were 0.1 excitative episodes per patients, which was statisti-
cally significant in comparison with previous treatments 
(P = 0.000 [t-test]).
No hospitalizations occurred during REAC-lithium 
treatment observation periods. The safety and tolerability 
profiles of combined REAC-lithium treatment were favorable 
in all patients. The overall clinical results before and after 
REAC augmentation of lithium are shown in Tables 2–5 and 
Figures 1–4. Rates of hospitalization before and after REAC 
augmentation of lithium are shown in Table 6.
Discussion
The major finding of this research was the superior effec-
tiveness of REAC-lithium treatment in comparison with the 
  corresponding previous treatment periods, in terms of depres-
sive rather than manic recurrences, in particular with respect 
to the comparison with lithium alone. It is interesting to note 
that this seems to be related to the REAC optimization of 
global brain functioning that is probably disrupted in bipolar 
depression as a consequence of previous manic-hypomanic 
episodes. The relevance of these results should be considered 
in relation to the well known drug resistance of this clinical 
disorder. The antidepressant activity of REAC-lithium 
treatment is the consequence of the action of the REAC 
device which, through the modulation of inter-intra neuronal 
microcurrents and microelectromagnetic fields,31 enables 
potentiation of the neurobiological activity of lithium.
Table 2 Demographic statistical, and mean values for the manic 
and depressive episodes, before and after reAc-lithium treatment 
in group 1 patients
Group 1 (n = 8)  
7 males [BD, I]  
1 females [BD, I]
Lithium REAC-Lithium
excitative episodes 2.1 ± 0.6 0.8 ± 0.4
Depressive episodes 3 ± 0.7 0.1 ± 0*
*t-Test: t = 11,718, DF14, P = 0.000.
Abbreviations:  BD,  bipolar  disorder;  reAc,  radioelectric  asymmetric  brain 
stimulation device.
Table 3 Demographic statistical, and mean values for the manic 
and depressive episodes, before and after reAc-lithium treatment 
in group 2 patients
Group 2 (n = 14)  
7 males (4 BD I and 3 BD II)  
7 females (all BD II)
Lithium REAC-Lithium
excitative episodes 2.4 ± 0.6 0.1 ± 0.2
Depressive episodes 3.9 ± 0.7 0 ± 0*
*t-Test: t = 20.846, DF26, P = 0.000.
Abbreviations:  BD,  bipolar  disorder;  reAc,  radioelectric  asymmetric  brain 
stimulation device.
Table 4 Demographic statistical, and mean values for the manic 
and depressive episodes, before and after reAc-lithium treatment 
in group 3 patients
Group 3 (n = 25)  
11 males [4 BD I and 7 BD II]  
14 females [3 BD I and 11 BD II]
Lithium REAC-Lithium
excitative episodes 2.6 ± 0.8 0.4 ± 0
Depressive episodes 3.6 ± 0.9 0 ± 0*
*t-Test: t = 20.000, DF48, P = 0.000.
Abbreviations:  BD,  bipolar  disorder;  reAc,  radioelectric  asymmetric  brain 
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Other work of ours in progress conducted with functional 
magnetic resonance images in healthy subjects asked to 
perform finger tapping has demonstrated a significant 
reduction of the cerebral areas involved in the planning, 
control, execution, and stopping of this motor task (Figures 5A 
and 5B). Thus, according to our studies, REAC allows for 
  better neural synchronization, such that less cerebral activity 
is needed to do the same movement. This deep cerebral 
activity of synchronization, as observed in normal subjects, 
is probably the main mechanism through which the REAC 
stabilizes the pathologic mood fluctuations in patients with 
bipolar disorder, so as to prevent morbid episodes, increase 
the duration of the so-called “free interval”, reduce the need 
for drug adjustments, to minimize the risk of hospitalizations. 
Our work shifts the focus from the biochemistry to the 
bioelectricity of the brain; it is important to emphasize 
that REAC seems synergic with lithium, which is not a 
drug but an ion, with an microelectric charge and a relative 
microelectromagnetic field. An interesting feature is that 
almost all patients included in the follow-up with REAC-
lithium treatment experienced longer free intervals compared 
with previous treatment periods. REAC-lithium treatment 
seems to be a good strategy suitable for the treatment of free 
intervals in bipolar disorder. Until now, the free interval in 
a bipolar patient is defined as status free from depression 
and mania, but more recently it has been suggested that the 
free interval is not free. It is known that, after some time, 
the majority of bipolar patients show various clinical signs 
which correspond closely with requests for therapeutic and/or 
dose adjustment, and this occurs even if depressive or manic 
mood phases are not ongoing. This phenomenon can be 
explained only and exclusively with the persistence of a global 
neurobiological instability, for which the quantitative and 
qualitative boundaries are unknown. Therefore, improvement 
of the free interval becomes the main objective in treatment 
of bipolar disorder. The role of REAC-lithium treatment 
during intercritic periods can be considered as a therapeutic 
effect not related to its antidepressant or antimanic activity, 
but strictly related to the global optimization of brain 
functioning, broadening its action target so as to spread to 
temporal prolongation, and to qualitative improvement of 
the free interval. Consequently, if improvement of the state of 
the bipolar patient during the intercritic phases is associated 
with a significantly reduced risk of depressive and manic 
recurrences, the intercritic period should become the primary 
Table 5 Demographic statistical, and mean values for the manic 
and depressive episodes, before and after reAc-lithium treatment 
in group 4 patients
Group 4 (n = 9)  
3 males [1 BD I and 2 BD II]  
6 females [2 BD I and 4 BD II]
Lithium REAC-Lithium
excitative episodes 2.6 ± 1.1 0.1 ± 0
Depressive episodes 3.7 ± 1 0 ± 0*
*t-Test: t = 11.100, DF16, P = 0.000.
Abbreviations:  BD,  bipolar  disorder;  reAc,  radioelectric  asymmetric  brain 
stimulation device.
Table 6 rate of hospitalization before and after reAc augmentation 
of lithium
Group 1 Group 2 Group 3 Group 4
Lithium 7 (5 D, 2 M) 9 (9 D) 7 (4 D, 3 M) 2 (1 D, 1 M)
reAc- 
lithium
0 0 0 0
Abbreviation: D, depressive episodes; M, excitative episodes; reAc, radioelectric 
asymmetric brain stimulation device.
Figure 1 Demographic statistical, and mean values for the manic and depressive 
episodes, before and after reAc-lithium treatment in group 1 patients.
Abbreviation: reAc, radioelectric asymmetric brain stimulation device.
Group 1 (n = 8)
Lithium REAC - Lithium
Treatment
0.5
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0.1
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Figure 2 Demographic statistical, and mean values for the manic and depressive 
episodes, before and after reAc-lithium treatment in group 2 patients.
Abbreviation: reAc, radioelectric asymmetric brain stimulation device.
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objective in treatment of bipolar disorder. Furthermore, the 
preventive action of REAC-lithium, both in terms of manic 
mood and depressive recurrences, seems to be progressively 
stronger over time. In fact, all the mood episodes happened 
within 24 months from the beginning of REAC-lithium 
treatment. This feature seems to be in conflict with the 
observations drawn from olanzapine and risperidone (but 
not for quetiapine), for which the clinical experience shows 
increasing development of therapeutic tolerance phenomena. 
In fact, the depressive episodes of bipolar disorder seem to 
predispose to development of new depressive episodes, and 
after some time, produce a chronic hypotimic picture. Bipolar 
depression is a clinical dilemma because affected patients 
are usually poor responders to traditional antidepressant 
treatments, ie, tricyclic antidepressants, selective serotonin 
reuptake inhibitors, and selective norepinephrine reuptake 
inhibitors. Furthermore, with an increased risk of manic 
switches, cycles speed up, and there is progressive prognostic 
deterioration.14,32 Therefore, in light of these real difficulties 
of treatment, it is very important to prevent the depressive 
episodes of bipolar disorder, and use of REAC is a very 
promising therapeutic modality. Small sample size, a 
naturalistic and flexible dose design, maintenance of lithium, 
and lack of accurate assessments were the main limitations of 
this study. Nevertheless, we suggest that naturalistic studies 
and not randomized clinical trials supply a correct picture of 
the routine medical practice with real patients and real-life 
situations.33 Moreover, the long duration of observation can 
better clarify the clinical evolution of bipolar disorder. The 
maintenance of lithium treatment associated with REAC is 
due to ethical and legal considerations in relation to the fact 
that bipolar disorder is a severe condition (ie, carries a suicide 
rate .20%), and REAC is effective, albeit not well studied 
as yet in Italy.
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Figure  5  Functional  magnetic  resonance  images  in  healthy  subjects  asked  to 
perform finger tapping. (A) Before reAc-NPO treatment and (B) after reAc-NPO 
treatment.
Abbreviations: NPO, neuropostural optimization; reAc, radioelectric asymmetric 
brain stimulation device.
A
Before REAC After REAC
B Group 3 (n = 25)
Lithium REAC - Lithium
Treatment
0.5
0
1
1.5
2.6
0.4
Excitative episodes
Depressive episodes
0
3.6
2
2.5
3
3.5
4
4.5
Figure 3 Demographic statistical, and mean values for the manic and depressive 
episodes, before and after reAc-lithium treatment in group 3 patients.
Abbreviation: reAc, radioelectric asymmetric brain stimulation device.
Figure  4  Demographic  statistical,  and  mean  values  for  the  manic  and  depressive 
episodes, before and after reAc-lithium treatment in group 4 patients.
Abbreviation: reAc, radioelectric asymmetric brain stimulation device.
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